Company news

Valneva SE news in 2025

Valneva SE's news releases, calls and decks from 2025, newest first.

View company

Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement

December 31, 2025

Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®

December 10, 2025

VALNEVA Declaration of shares and voting rights: November 30, 2025

December 5, 2025

Valneva to Further Consolidate its Operations in France

November 26, 2025

Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate

November 26, 2025

Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates

November 20, 2025

VALNEVA Declaration of shares and voting rights: October 31, 2025

November 5, 2025

Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate

November 4, 2025

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

October 27, 2025

Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates

October 6, 2025

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®

September 30, 2025

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate

September 3, 2025

Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.

August 25, 2025

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

August 18, 2025

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

August 12, 2025

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information

August 7, 2025

VALNEVA Declaration of shares and voting rights: July 31, 2025

August 5, 2025

Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly

July 11, 2025

VALNEVA Declaration of shares and voting rights: June 30, 2025

July 3, 2025

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus

June 26, 2025

Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance

June 25, 2025

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

June 5, 2025

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

June 4, 2025

Valneva to Participate at U.S. and European Investor Conferences in June

May 26, 2025

Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States

May 12, 2025

Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly

May 7, 2025

Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 7, 2025

Calls in 2025

Decks in 2025